$SEPN News

Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Septerna to Participate in Upcoming Investor Conferences

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

JP Morgan Maintains Overweight on Septerna, Raises Price Target to $48

Jones Trading Maintains Buy on Septerna, Raises Price Target to $62

Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $50

HC Wainwright & Co. Maintains Buy on Septerna, Raises Price Target to $60

Guggenheim Maintains Buy on Septerna, Raises Price Target to $51

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Septerna Q2 EPS $(0.29) Beats $(0.43) Estimate, Sales $26.746M Beat $17.875M Estimate

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment?

Guggenheim Maintains Buy on Septerna, Lowers Price Target to $45

HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target

Truist Securities Maintains Buy on Septerna, Raises Price Target to $43

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Septerna: A De-Risking GPCR Story With Near-Term Upside Catalysts

Raymond James Maintains Strong Buy on Septerna, Raises Price Target to $53